Evidence map›Paper›PMID 38009004›Full record

ArticleActa biochimica et biophysica Sinica2023

Dihydrocelastrol induces antitumor activity and enhances the sensitivity of bortezomib in resistant multiple myeloma by inhibiting STAT3-dependent PSMB5 regulation.

Shuhan Jin, Bo Li, Bibo Zhang, Xuejie Gao, Xinyan Jia, Li Xu, Shuaikang Chang, Ke Hu, Guanli Wang, Zhijian Xu and 10 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta biochimica et biophysica Sinica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.7field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 5 institutions in 1 country.

Shuhan JinDepartment of Hematology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
Bo LiState Key Laboratory of Drug Research, Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Bibo ZhangDepartment of Hematology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
Xuejie GaoDepartment of Hematology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
Xinyan JiaDepartment of Hematology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
Li XuDepartment of Hematology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
Shuaikang ChangDepartment of Hematology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
Ke HuDepartment of Hematology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
Guanli WangDepartment of Hematology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
Zhijian XuState Key Laboratory of Drug Research, Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Ting ZhangDepartment of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China.
Dongliang SongDepartment of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China.
Guang YangDepartment of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China.
Xiaosong WuDepartment of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China.
Huabin ZhuDepartment of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China.
Cheng HuangDepartment of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China.
Yumeng LuDepartment of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China.
Jumei ShiDepartment of Hematology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
Weiliang ZhuState Key Laboratory of Drug Research, Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Gege ChenDepartment of Hematology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
Shanghai East Hospital · CNShanghai Tenth People's Hospital · CNTongji University · CNChinese Academy of Sciences · CNShanghai Institute of Materia Medica · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple myeloma (MM) is characterized by excessive aggregation of B-cell-derived malignant plasma cells in the hematopoietic system of bone marrow. Previously, we synthesized an innovative molecule named dihydrocelastrol (DHCE) from celastrol, a triterpene purified from medicinal plant

Indexed as

Antineoplastic AgentsMultiple MyelomaApoptosisBortezomibCell Line, TumorCell ProliferationDrug Resistance, NeoplasmHumansPentacyclic TriterpenesPhosphatidylinositol 3-KinasesProteasome Endopeptidase ComplexSTAT3 Transcription FactorAntineoplastic AgentsBortezomibcelastrolPentacyclic TriterpenesPhosphatidylinositol 3-KinasesProteasome Endopeptidase ComplexPSMB5 protein, humanSTAT3 protein, humanSTAT3 Transcription Factorbortezomib resistancedihydrocelastrolJAK2/STAT3multiple myelomaPSMB5

Identifiers

PMID38009004
PMCPMC11294055
OpenAlexW4389032366

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.